Вопросы сердечно-сосудистой безопасности длительной терапии тиотропием пациентов с ХОБЛ

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Last updated 2009. www.goldcopd.org/
2. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932–46.
3. Buist AS, McBurnie MA, Vollmer WM et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741–50.
4. Чучалин А.Г. Клинические рекомендации по хронической обструктивной болезни легких. М.: Медицинская книга, 2001.
5. Panning CA, De Bisschop M. Tiotropium: an inhaled, long-acting anticholinergic drug for chronic obstructive pulmonary disease. Pharmacotherapy 2003; 23: 183–9.
6. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin Pulm Med 2010; 16: 97–105.
7. Olin JL. Tiotropium: An inhaled anticholinergic for chronic obstructive pulmonary disease. Am J Health-Syst Pharm 2005; 62: 1263–9.
8. Gross NJ. Chronic obstructive pulmonary disease: an evidence- based approach to treatment with a focus on anticholinergic bronchodilation. Mayo Clin Proc 2008; 83: 1241–50.
9. Heredia JL. Tiotropium bromide: an update. The Open Respiratory Medicine Journal 2009; 3: 43–52.
10. Hilleman DE, Malesker MA, Morrow LE, Schuller D. A systematic review of the cardiovascular risk of inhaled anticholinergics in patients with COPD. Int J COPD 2009; 4: 253–63.
11. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease. A systematic review and meta-analysis. JAMA 2008; 300: 1439–50.
12. Lee TA, Pickard AS, Bartle B, Weiss K. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Int Med 2008; 149: 380–9.
13. Oba Y, Zaza T, Thameem DM. Safety, tolerability, and risk benefit analysis of tiotropium in COPD. Int J COPD 2008; 3: 575–84.
14. Anthonisen MNR, Connett JE, Enright PF et al. Hospitalization and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333–9.
15. Lee TA, Wilke C, Joo M et al. Outcomes associated with tiotropium use in patients with chronic obstructive pulmonary disease. Arch Intern Med 2009; 169: 1403–10.
16. de Luise C, Lanes SF, Jacobsen J et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidem 2007; 22: 267–72.
17. Gershon AS, Wang L, To T et al. Survival with tiotropium compared to long-acting beta-2-agonists in chronic obstructive pulmonary disease. J COPD 2008; 5: 229–34.
18. Salpeter SR, Buckley NS, Salpeter EE. Meta-analysis: anticholinergics, but not beta-agonists, reduce severe exacerbations and respiratory mortality in COPD. J Gen Int Med 2006; 21: 1011–9.
19. Kesten S, Celli B, Decramer M et al. Tiotropium HandiHaler® in the treatment of COPD: A safety review. Int J COPD 2009; 4: 397–409.
20. Tashkin DP, Celli B, Senn SDB et al. A 4-year trial of tiotropium in Chronic Obstructive Pulmonary Disease. N Engl J Med 2008; 359: 1543–54.
21. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium − the FDA’s conclusions. N Engl J Med 2010; 363; 1097–9.
22. Celli B, Decramer M, Leimer I et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010; 137; 20–30.
23. Short PM, Williamson PA, Elder DHJ et al. The impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting b-agonist therapy in COPD. Chest 2012; 141: 81–6.
24. Watz H, Waschki B, Meyer T et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD. Role of hyperinflation. Chest 2010; 138: 32–8.
25. Vassaux C, Torre-Bouscoulet L, Zeineldine S et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J 2008; 32: 1275–82.
26. Criner GJ, Scharf SM, Falk JA; National Emphysema Treatment Trial Research Group, et al. Effect of lung volume reduction 
surgery on resting pulmonary hemodynamics in severe emphysema. Am J Respir Crit Care Med 2007; 176: 253–60.
27. Jörgensen K, Houltz E, Westfelt U et al. Effects of lung volume reduction surgery on left ventricular diastolic filling and dimensions in patients with severe emphysema. Chest 2003; 124: 1863–70.
28. O’Donnell DE, Fluge T, Gerken F et al. Effects of tiotropium on lung hyperinflation, dyspnea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–40.
29. Donaldson GC, Hurst JR, Smith CJ et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091–7.
30. Dusser D, Bravo M-L, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2005; 27: 547–55.
31. Niewoehner DE, Rice K, Cote C et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once daily inhaled anticholinergic bronchodilator – a randomized trial. Ann Intern Med 2005; 143: 317–26.
32. Powrie DJ, Wilkinson TMA, Donaldson GC et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur Respir J 2007; 30: 472–8.

С.Н.Авдеев 

ФГУ НИИ пульмонологии ФМБА России, Москва